Impact of the botulinum-A toxin on prevention of adult migraine disorders
A systematic review of the impact of botulinum-A toxin as a therapeutic regimen for the management of adult migraine disorders is shown to that Botulinum-A toxin provides a more significant reduction in the number of headache episodes per month relative to placebo (MD: -0.61, 95% CI: -1.02 to -0.19)...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2020-03-01
|
| Series: | Journal of Integrative Neuroscience |
| Subjects: | |
| Online Access: | https://jin.imrpress.com/fileup/1757-448X/PDF/1585708671041-537712558.pdf |
| _version_ | 1818200161780760576 |
|---|---|
| author | Bin Shen, Lan Wang |
| author_facet | Bin Shen, Lan Wang |
| author_sort | Bin Shen, Lan Wang |
| collection | DOAJ |
| description | A systematic review of the impact of botulinum-A toxin as a therapeutic regimen for the management of adult migraine disorders is shown to that Botulinum-A toxin provides a more significant reduction in the number of headache episodes per month relative to placebo (MD: -0.61, 95% CI: -1.02 to -0.19). In subgroup analysis, botulinum-A toxin significantly reduced headache episodes per month relative to placebo for chronic migraine (MD: -1.68, 95% CI: -3.31 to -0.06), migraine (MD: -2.43, 95% CI: -4.08 to -0.77), and follow-up time in 16 weeks (MD: -2.19, 95% CI: -3.84 to -0.53). Statistical differences were not found in subgroup analyses of data relating to chronic migraine, episodic migraine, and other treatment course durations. An analysis of chronic and episodic migraine, botulinum-A toxin did not significantly differ from placebo in the proportion of patients achieving a fifty percent reduction in the number of headaches per month. In terms of patients' subjective reporting of headaches, botulinum toxin A conferred significant improvements when assessment questionnaires of migraine disability and migraine impact were analyzed. However, differences were not substantial with data from the 6-item headache impact test. This meta-analysis demonstrated that botulinum-A toxin as a therapeutic regimen improved the impact of chronic migraines after 16 weeks of therapy, although this was not the case for episodic migraine. |
| first_indexed | 2024-12-12T02:33:16Z |
| format | Article |
| id | doaj.art-b876eba9dd6e40afa6449da1bfc9f86b |
| institution | Directory Open Access Journal |
| issn | 1757-448X |
| language | English |
| last_indexed | 2024-12-12T02:33:16Z |
| publishDate | 2020-03-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Journal of Integrative Neuroscience |
| spelling | doaj.art-b876eba9dd6e40afa6449da1bfc9f86b2022-12-22T00:41:21ZengIMR PressJournal of Integrative Neuroscience1757-448X2020-03-0119120120810.31083/j.jin.2020.01.1240Impact of the botulinum-A toxin on prevention of adult migraine disordersBin Shen, Lan Wang01 Jiangsu Vocational College of Medicine, Yancheng, 224005, P. R. China;2 Hubei University of Chinese Medicine, Wuhan, 430065, P. R. China;3 Institute of Chinese Medicine Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, 430061, P. R. ChinaA systematic review of the impact of botulinum-A toxin as a therapeutic regimen for the management of adult migraine disorders is shown to that Botulinum-A toxin provides a more significant reduction in the number of headache episodes per month relative to placebo (MD: -0.61, 95% CI: -1.02 to -0.19). In subgroup analysis, botulinum-A toxin significantly reduced headache episodes per month relative to placebo for chronic migraine (MD: -1.68, 95% CI: -3.31 to -0.06), migraine (MD: -2.43, 95% CI: -4.08 to -0.77), and follow-up time in 16 weeks (MD: -2.19, 95% CI: -3.84 to -0.53). Statistical differences were not found in subgroup analyses of data relating to chronic migraine, episodic migraine, and other treatment course durations. An analysis of chronic and episodic migraine, botulinum-A toxin did not significantly differ from placebo in the proportion of patients achieving a fifty percent reduction in the number of headaches per month. In terms of patients' subjective reporting of headaches, botulinum toxin A conferred significant improvements when assessment questionnaires of migraine disability and migraine impact were analyzed. However, differences were not substantial with data from the 6-item headache impact test. This meta-analysis demonstrated that botulinum-A toxin as a therapeutic regimen improved the impact of chronic migraines after 16 weeks of therapy, although this was not the case for episodic migraine.https://jin.imrpress.com/fileup/1757-448X/PDF/1585708671041-537712558.pdf|migraine|botulinum-a toxin|headache episodes|treatment-related adverse events|meta-analysis |
| spellingShingle | Bin Shen, Lan Wang Impact of the botulinum-A toxin on prevention of adult migraine disorders Journal of Integrative Neuroscience |migraine|botulinum-a toxin|headache episodes|treatment-related adverse events|meta-analysis |
| title | Impact of the botulinum-A toxin on prevention of adult migraine disorders |
| title_full | Impact of the botulinum-A toxin on prevention of adult migraine disorders |
| title_fullStr | Impact of the botulinum-A toxin on prevention of adult migraine disorders |
| title_full_unstemmed | Impact of the botulinum-A toxin on prevention of adult migraine disorders |
| title_short | Impact of the botulinum-A toxin on prevention of adult migraine disorders |
| title_sort | impact of the botulinum a toxin on prevention of adult migraine disorders |
| topic | |migraine|botulinum-a toxin|headache episodes|treatment-related adverse events|meta-analysis |
| url | https://jin.imrpress.com/fileup/1757-448X/PDF/1585708671041-537712558.pdf |
| work_keys_str_mv | AT binshenlanwang impactofthebotulinumatoxinonpreventionofadultmigrainedisorders |